Literature DB >> 18679811

Differential expression of angiogenic factors in peripheral nerve sheath tumors.

Junji Wasa1, Yoshihiro Nishida, Yoshitaka Suzuki, Satoshi Tsukushi, Yoji Shido, Kozo Hosono, Yoshie Shimoyama, Shigeo Nakamura, Naoki Ishiguro.   

Abstract

It is difficult to differentiate some malignant peripheral nerve sheath tumors (MPNST) from benign peripheral nerve sheath tumors (BPNST) histologically, and to predict the clinical outcome of patients with MPNST. In this study, the expression of VEGF and MVD were evaluated immunohistochemically in 22 cases of MPNST, 14 of neurofibroma and 19 of schwannoma and correlation of the staining grade of VEGF or MVD and the various clinical factors were analyzed, and statistically evaluated. Levels of VEGF mRNA expression were also determined with real-time RT-PCR. Statistically higher positive staining for VEGF was observed in MPNST compared to neurofibroma (P=0.004) and schwannoma (P<0.001). Even low grade MPNST showed higher VEGF positive staining than neurofibroma. Moreover, high VEGF expression statistically correlated with the poor prognosis of the patients with MPNST (P=0.015). Although MVD in MPNST was significantly higher than that in neurofibroma (P=0.038) and schwannoma (P<0.001), MVD could not predict the prognosis of the patients with MPNST. Although VEGF mRNA expression tended to be higher in MPNST compared to neurofibroma, the difference was not significant. Levels of VEGF protein expression serve as a novel diagnostic and prognostic tools for peripheral nerve sheath tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679811     DOI: 10.1007/s10585-008-9197-8

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  31 in total

1.  Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade.

Authors:  C Chao; T Al-Saleem; J J Brooks; A Rogatko; W G Kraybill; B Eisenberg
Journal:  Ann Surg Oncol       Date:  2001-04       Impact factor: 5.344

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

3.  Prognostic significance of angiogenesis in gastrointestinal stromal tumor.

Authors:  Masakazu Imamura; Hidetaka Yamamoto; Norimoto Nakamura; Yoshinao Oda; Takashi Yao; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara; Masazumi Tsuneyoshi
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

4.  [Correlation of tumor microvesseldensity with prognosis in osteogenic sarcoma].

Authors:  D Wang; L Chen; F Gao
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  1997-10

5.  Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis.

Authors:  M Kaya; T Wada; T Akatsuka; S Kawaguchi; S Nagoya; M Shindoh; F Higashino; F Mezawa; F Okada; S Ishii
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

6.  Prognostic relevance of increased angiogenesis in osteosarcoma.

Authors:  Michael Kreuter; Ralf Bieker; Stefan S Bielack; Tanja Auras; Horst Buerger; Georg Gosheger; Heribert Jurgens; Wolfgang E Berdel; Rolf M Mesters
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

7.  Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas.

Authors:  Emilios E Pakos; Ann C Goussia; Pericles G Tsekeris; Dionysios J Papachristou; Dimitrios Stefanou; Niki J Agnantis
Journal:  Anticancer Res       Date:  2005 Sep-Oct       Impact factor: 2.480

8.  Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases.

Authors:  J E Wanebo; J M Malik; S R VandenBerg; H J Wanebo; N Driesen; J A Persing
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

9.  Analysis of vascularity of human neurofibromas.

Authors:  J L Arbiser; E Flynn; R L Barnhill
Journal:  J Am Acad Dermatol       Date:  1998-06       Impact factor: 11.527

10.  Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.

Authors:  T C Mineo; V Ambrogi; A Baldi; C Rabitti; P Bollero; B Vincenzi; G Tonini
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

View more
  6 in total

1.  Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors.

Authors:  Kunihiro Ikuta; Hiroshi Urakawa; Eiji Kozawa; Eisuke Arai; Lisheng Zhuo; Naohisa Futamura; Shunsuke Hamada; Koji Kimata; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2014-06-24       Impact factor: 5.150

2.  The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Authors:  Jan Zietsch; Nicolas Ziegenhagen; Frank L Heppner; David Reuss; Andreas von Deimling; Nikola Holtkamp
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

3.  Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.

Authors:  Suguru Fukushima; Makoto Endo; Yoshihiro Matsumoto; Jun-Ichi Fukushi; Tomoya Matsunobu; Ken-Ichi Kawaguchi; Nokitaka Setsu; Keiichiro IIda; Nobuhiko Yokoyama; Makoto Nakagawa; Kenichiro Yahiro; Yoshinao Oda; Yukihide Iwamoto; Yasuharu Nakashima
Journal:  PLoS One       Date:  2017-05-30       Impact factor: 3.240

4.  Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review.

Authors:  Enrico Martin; Ibtissam Acem; Dirk J Grünhagen; Judith V M G Bovée; Cornelis Verhoef
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

Review 5.  Translating current basic research into future therapies for neurofibromatosis type 1.

Authors:  Jean-Philippe Brosseau; Chung-Ping Liao; Lu Q Le
Journal:  Br J Cancer       Date:  2020-05-22       Impact factor: 7.640

Review 6.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.